Search

Displaying results 6081 - 6090 of 9333 in total
  1. Drug

    Urefibrate

    go.drugbank.com/drugs/DB20849
    Experimental

    The usage of the INN stem '-fibrate' in the name indicates that Urefibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist.

  2. Drug

    Sitofibrate

    go.drugbank.com/drugs/DB21192
    Experimental

    The usage of the INN stem '-fibrate' in the name indicates that Sitofibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist.

  3. Drug

    Zatonacaftor

    go.drugbank.com/drugs/DB21625
    Experimental

    The usage of the INN stem '-caftor' in the name indicates that Zatonacaftor is a Cystic fibrosis transmembrane regulator (CFTR) protein modulator, corrector, and amplifier.

  4. Drug

    SARS-CoV-2 Sclamp

    go.drugbank.com/drugs/DB15849
    Investigational

    TetraQ, Australian National University (ANU), the University of Melbourne, and the Peter Doherty Institute for Infection and Immunity are also involved in the clinical component. … Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and induced a strong T-cell response.

  5. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis

  6. Drug

    AZD 3355

    go.drugbank.com/drugs/DB05404
    Investigational

    AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.

  7. Drug

    GTI-2501

    go.drugbank.com/drugs/DB05406
    Experimental

    The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer.

  8. Drug

    Ponazuril

    go.drugbank.com/drugs/DB11452
    ExperimentalVet approved

    Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.

  9. Drug

    E1v1.11

    go.drugbank.com/drugs/DB18363
    Experimental

    E1v1.11 is an antisense oligonucleotide targeting the _SMN2_ gene which is under investigation for the treatment of spinal muscular atrophy (SMA).[L48196]

  10. Drug

    SPP1148

    go.drugbank.com/drugs/DB05203
    Experimental

    SPP1148, the most promising compound from a new series of renin inhibitors for the treatment of hypertension and related end-organ disease.